$56.14
+0.28
(+0.5%)▲
2.25%
Downside
Day's Volatility :2.86%
Upside
0.62%
62.06%
Downside
52 Weeks Volatility :62.81%
Upside
1.99%
Period | Soleno Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | 23.34% | 0.0% |
6 Months | 21.59% | 0.0% |
1 Year | 141.71% | 0.0% |
3 Years | 366.02% | -26.4% |
Market Capitalization | 2.2B |
Book Value | $7.31 |
Earnings Per Share (EPS) | -1.83 |
PEG Ratio | 0.0 |
Wall Street Target Price | 73.13 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.55% |
Return On Equity TTM | -44.62% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -66.5M |
Diluted Eps TTM | -1.83 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.42 |
EPS Estimate Next Year | -2.08 |
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Next Quarter | -0.62 |
What analysts predicted
Upside of 30.26%
Sell
Neutral
Buy
Soleno Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Soleno Therapeutics Inc | 12.55% | 21.59% | 141.71% | 366.02% | 140.26% |
Regeneron Pharmaceuticals, Inc. | -16.71% | -12.0% | 1.34% | 30.26% | 171.22% |
Biontech Se | -9.13% | 19.42% | 11.8% | -59.3% | 487.66% |
Alnylam Pharmaceuticals, Inc. | 2.21% | 81.13% | 63.87% | 47.62% | 198.57% |
Vertex Pharmaceuticals Incorporated | 3.47% | 17.05% | 22.13% | 142.58% | 136.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Soleno Therapeutics Inc | NA | NA | 0.0 | -2.42 | -0.45 | -0.26 | NA | 7.31 |
Regeneron Pharmaceuticals, Inc. | 20.75 | 20.75 | 1.18 | 44.77 | 0.17 | 0.08 | NA | 242.47 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Soleno Therapeutics Inc | Buy | $2.2B | 140.26% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $101.7B | 171.22% | 20.75 | 32.04% |
Biontech Se | Buy | $27.1B | 487.66% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 198.57% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 136.25% | 32.84 | -4.74% |
Vivo Capital, LLC
Nantahala Capital Management, LLC
The Carlyle Group Inc
HHG PLC
Perceptive Advisors LLC
Adage Capital Partners Gp LLC
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
Organization | Soleno Therapeutics Inc |
Employees | 33 |
CEO | Dr. Anish Bhatnagar M.D. |
Industry | Health Technology |
Victoryshares International
$56.14
+0.5%
Clearbridge Focus Value Esg Etf
$56.14
+0.5%
Cabana Target Drawdwn 10 Etf
$56.14
+0.5%
Spdr Nyse Technology Etf
$56.14
+0.5%
Global Ship Lease Inc-cl A
$56.14
+0.5%
Standard Motor Products Inc
$56.14
+0.5%
Cp High Yield Trend Etf
$56.14
+0.5%
Gain Therapeutics Inc
$56.14
+0.5%
Olaplex Holdings, Inc.
$56.14
+0.5%